GlassScriptPhysician profile
Bernadette Huvane
NPI 1285761270
$2,017.93
in general payments reported to CMS, 2019-2025
15 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $388 · 2023: $250 · 2024: $240 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $225.00 | 2021-2023 | |
| Madrigal Pharmaceuticals | $150.00 | 2025 | Rezdiffra |
| Abbott Laboratories | $146.31 | 2025 | Freestyle Libre 3 |
| Biomerieux INC | $142.00 | 2025 | Biofire Respiratory Panel 2.1 |
| Coloplast Corp | $134.45 | 2022 | |
| Genzyme Corporation | $128.42 | 2022 | |
| Depuy Synthes Sales INC. | $125.87 | 2024 | Expedium, Teligen, Symphony |
| Ani Pharmaceuticals, INC. | $125.01 | 2023 | Purified Cortrophin Gel |
| Ucb, INC. | $125.00 | 2025 | Nayzilam |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $123.93 | 2025 | Entyvio |
| Dexcom, INC. | $114.30 | 2024 | Dexcom G7 Gss (161) |
| Eisai INC. | $102.64 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bernadette Huvane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.